|
|
|
| How CDMOs Are Changing to Meet the Needs of Biotech Companies. | CDMOs have shifted from transactional vendors to strategic scientific partners, supporting increasing development complexity and rising regulatory expectations. Read how challenges to delivery models and partnerships are shaping more predictable, transparent programmes for biotech innovators. |
|
|
|
|
| The Impact Of PEGs In The Small Molecule API Market | Webinar | MilliporeSigma | Explore how PEG selection shapes drug development success by understanding the benefits of expert CDMO partnerships that deliver custom solutions to enhance your small molecule program. |
|
|
| Patient Adherence With A Novel Dosage Form | Case Study | Adare Pharma Solutions | A sprinkle formulation helps patients with tremors or dysphagia take medication more easily, improving adherence, comfort, and care through a novel, FDA-approved oral granule format. |
|
|
|
|
By Jeffrey S. Buguliskis, Ph.D., deputy chief editor, Outsourced Pharma | As biopharma pipelines shift toward more complex therapies, sponsors are finding that CDMO readiness now depends less on general capacity and more on highly specific technical capabilities. | |
|
|
|
INDUSTRY INSIGHTS CONTINUED |
|
|
| Taking A Best Practice Approach To Contamination Control | Article | West Pharmaceutical Services, Inc. | Implementing the EU GMP Annex 1 requires a holistic, evolutionary contamination control strategy built on standardization, data analytics, and continuous improvement for a zero-defect mindset. |
|
|
|
|
|
|
|
|
OUTSOURCED PHARMA CAPABILITIES UPDATE |
|
|
|
CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capabilities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs. |
|
|
| Connect With Outsourced Pharma: |
|
|
|
